Rigel Pharmaceuticals, Inc. Stock Analysis & AI Score
Rigel Pharmaceuticals, Inc. (RIGL) has an ST Score of 51.7 (C+), driven by its Profitability (A+) and held back by its Financial Strength (D-). Analysts rate it Buy with a $67.00 price target (+39.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Rigel Pharmaceuticals, Inc. (RIGL) has an ST Score of 51.7 (C+), driven by its Profitability (A+) and held back by its Financial Strength (D-). Analysts rate it Buy with a $67.00 price target (+39.9% upside).
- Strongest
- ProfitabilityA+
- Weakest
- Financial StrengthD-
All factor grades
- ProfitabilityA+
- MomentumA-
- GrowthB
- ForecastB
- ValuationD-
- Financial StrengthD-
- Piotroski4/9
Contact
RIGL stock: frequently asked questions
What is RIGL's ST Score?
Rigel Pharmaceuticals, Inc. (RIGL) has an ST Score of 51.7 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RIGL a buy, hold, or sell?
Analysts rate RIGL a Buy, with a price target of $67.00 (+39.9% vs the current price). Our ST Score grades it C+ (51.7/100). The ST Score is a data-driven signal, not a recommendation.
What are RIGL's factor grades?
Valuation D-, Profitability A+, Financial Strength D-, Momentum A-, Growth B, Forecast B.
What is RIGL's valuation grade?
Rigel Pharmaceuticals, Inc. (RIGL) earns a valuation grade of D-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RIGL's growth grade?
Rigel Pharmaceuticals, Inc. (RIGL) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RIGL's profitability grade?
Rigel Pharmaceuticals, Inc. (RIGL) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RIGL's financial strength grade?
Rigel Pharmaceuticals, Inc. (RIGL) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RIGL?
The average analyst price target for Rigel Pharmaceuticals, Inc. (RIGL) is $67.00 from 15 analysts, which is +39.9% versus the recent price of $47.89.
What is RIGL's Piotroski score?
Rigel Pharmaceuticals, Inc. (RIGL) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.